10x Genomics CEO Serge Saxonov sells $667,900 in stock

Serge Saxonov, CEO of 10x Genomics, sold 10,486 shares of Class A Common Stock on August 26, 2026. The sales, conducted under a pre-approved Rule 10b5-1 trading plan, totaled around $667,900, with shares traded at prices between $63.0229 and $64.7465 per share. This move occurred as TXG shares hovered near their 52-week high of $66.94, following a 339% increase over the past year.

InvestingPro analysts currently deem the stock overvalued, suggesting a 12 ProTips for subscribers. Post-transactions, Saxonov retains 1,075,349 shares Class A Common Stock, along with indirect ownership through various trusts. Meanwhile, 10x Genomics reported stronger-than-expected Q2 2026 results, generating $151.04 million in revenue, and an adjusted loss of $0.14 per share, surpassing analysts' forecasts.

Despite the positive financial outlook, the company's stock saw a decline post-announcement, attributed to investor concerns about near-term performance and the platform transition. Notably, Canaccord raised its price target from $50 to $60, affirming a Buy rating and indicating a 15% upside potential, driven by medium- to long-term revenue and margin expectations in AI and biopharma sectors.